US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 22, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 16, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
May 15, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
May 12, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
May 11, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
May 08, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
April 27, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
April 26, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
April 24, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
April 04, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
March 09, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
February 22, 2023
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
December 19, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
November 28, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
November 16, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
November 09, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
October 24, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
September 12, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
August 29, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
August 16, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
August 08, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
August 03, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
July 28, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
July 25, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
July 18, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
June 22, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
June 02, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
June 01, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
May 20, 2022
From
ANI Pharmaceuticals, Inc.
Via
Business Wire
Tickers
ANIP
